Filing Flows › GSK (GSK) › Q3 2025
GSK (GSK) Q3 2025 earnings results (third quarter 2025)
6-K filed Oct 29, 2025
GSK (GSK) reported revenue of $8.5B for the third quarter 2025 (Q3 2025), +7% from a year earlier and +7% from the quarter before. Operating margin was 30.3%, net earnings $2.0B (23.6% of revenue).
GSK, Q3 2025: revenue $8.5B (+7% year over year), operating margin 30.3%, net earnings $2.0B, operating cash flow $2.5B. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.5B | +7% | +7% |
| Gross profit | $6.3B | +8% | +12% |
| Operating profit | $2.6B | +28% | 14× |
| Net earnings | $2.0B | +40% | — |
| Operating cash flow | $2.5B | +4% | 2,520× |
What changed
Revenue was £8.5B in Q3 2025, up 7% year over year and up 7% from the previous quarter. HIV was the largest line at 23% of revenue.
Gross margin was 73.6%, up 3.5 points from a year earlier. Operating profit was £2.6B, a 30.3% margin (up 28.0 points year over year). Of the extra revenue versus a year earlier, 449% reached operating profit, above the 2% margin then. Operating expenses fell 32% while revenue rose 7%. Net earnings were £2.0B. The effective tax rate was 12.7%.
Operating cash flow was £2.5B (up 251900% year over year), 118% of net income including minority interests. Working capital and other items added £0.38B.
Questions
What was GSK's revenue in the third quarter 2025?
GSK (GSK) reported revenue of $8.5B for the third quarter 2025 (Q3 2025), +7% from a year earlier and +7% from the quarter before.
Was GSK profitable in the third quarter 2025?
Operating profit was $2.6B (30.3% of revenue) and net earnings $2.0B.
Source: GSK 6-K on SEC EDGAR.